Aesthetics Journal: Revance Therapeutics Commences Botulinum Toxin Topical Gel Trial For Canthal Lines

Biopharmaceutical company Revance Therapeutics has begun a phase 3 study to evaluate the safety and efficacy of a topical drug candidate for the treatment of lateral canthal lines. Biopharmaceutical company Revance Therapeutics has begun a phase 3 study to evaluate the safety and efficacy of a topical drug candidate for the treatment of lateral canthal … Continue reading Aesthetics Journal: Revance Therapeutics Commences Botulinum Toxin Topical Gel Trial For Canthal Lines

Aesthetics Journal: Novan Therapeutics Announces Success Of Acne Nitric-Oxide Based Drug

Biotechnology company Novan Therapeutics has announced that it has received encouraging results from a phase 2b study analysing a nitric-oxide topical gel candidate drug.  SB204, which is the company’s leading drug candidate for the treatment of acne vulgaris, was used in the trial and produced significant results on inflammatory and non-inflammatory lesions at week 12 … Continue reading Aesthetics Journal: Novan Therapeutics Announces Success Of Acne Nitric-Oxide Based Drug